#ACTRIMS2017

March 6, 2017March 6, 2017

Altered Immune Response in MS Is What May Allow Infections to Kill, Mouse Study Suggests

News

It is no coincidence that multiple sclerosis (MS) patients are prone to airway infections, according to research showing that MS disease processes allow suppressive immune cells ... Read more

March 1, 2017March 1, 2017

#ACTRIMS2017 – Gut Microbiome Gains Researchers’ Interest as Possible MS Therapy

Columns, Engaging Thoughts

The role of the microbiome and its association with multiple sclerosis was the topic of several sessions and papers at the Americas Committee for Treatment and ... Read more

March 1, 2017March 1, 2017

Acthar Gel of Dubious Value in Treating MS Despite its $34,000-Per-Vial Cost, Study Finds

News

Medicare spent more $650 million in 2013 and 2014 on one single medication — H.P. Acthar Gel —— that was prescribed by fewer than 1 percent of clinicians to ... Read more

February 28, 2017February 28, 2017

#ACTRIMS2017 – MS, the Gut and Probiotics

Engaging Thoughts, News

Harold Weiner, MD, believes in using probiotics to help treat multiple sclerosis. He is such a believer that he did a presentation on the subject — “Probiotics ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Smoking Significantly Worsens Quality of Life for MS Patients, Study Shows

News

Multiple sclerosis (MS) patients who smoke have a significantly worse quality of life than non-smoking MS patients, concludes a new study. Researchers presented the study, “Smokers with MS ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Study Reports Possible Link Between Viral Infections, Vitamin D, and Risk for MS

News

In a U.S. nationwide case study, a team of researchers found evidence for a potential link between viral infections during childhood, vitamin D deficiency, and the risk of developing multiple ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – 60-year Follow-up Study of MS Patients Looked at Risks, Causes of Death

News

A 60-year follow-up study of nearly 1,400 Norwegian patients with multiple sclerosis (MS) analyzed their survival and risk of dying starting with the onset of the disease ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Keynote Lecture Focused on Two Disease-Modifying Therapies

Columns, Engaging Thoughts

Editor’s note: Columnist Laura Kolaczkowski writes from the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in Orlando, Fla., (Feb. 23-25). Two MS disease-modifying ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

News

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Novantrone Lowers Relapse Rates over Long Term, But Carries Cancer Risk

News

Ten years after completing treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lower annualized relapse rates, but the therapy’s effects began ... Read more

February 27, 2017February 27, 2017

#ACTRIMS2017 – Epigenetics’ Role in Myelin Renewal Is Focus of Research

News

The absence of epigenetic factors in myelin-producing oligodendrocyte cells make sure that myelin production is switched off in the adult brain. Targeting these factors may be ... Read more

February 24, 2017February 25, 2017

#ACTRIMS2017: Support for Vitamin D Supplements Grows

Columns, Engaging Thoughts

Evidence supporting the use of Vitamin D for people with multiple sclerosis continues to grow but there remains many unanswered questions as well. Ellen Mowry, MD, ... Read more

February 24, 2017February 27, 2017

#ACTRIMS2017 – There is Increased Evidence Linking Viruses to MS Risk

News

Multiple sclerosis (MS) is thought to be caused by genetic factors, but environmental cues are increasingly recognized to have an impact on disease onset and development. ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – Sex Hormones and Chromosomes Lead to Gender Differences in MS, Studies Report

News

Sex hormones, and genes in the two sex chromosomes, impact the risk of multiple sclerosis (MS) in men and women differently, and lead to differences in ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – High Salt Diet Seen as Potential Risk Factor for MS in New Study

News

New evidence strengthens the link between a diet high in salt and multiple sclerosis (MS) development, researchers show. The study, “Sodium Chloride Intake and MS,” was presented on ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – 3 Trials Show MS Patients Receiving Ocrevus Had No Elevated Infection Risk

News

A detailed analysis of relapsing and primary progressive multiple sclerosis (MS) patients in the three Phase 3 trials of Ocrevus (ocrelizumab) showed that the treatment did not ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – Some Fatty Acids in Diet Help, Others Hurt Immune System, Study Reports

News

Short-chain dietary fatty acids, such as propionate, drive the production of regulatory immune T-cells in patients with multiple sclerosis (MS), while long-chain acids promote T-cells that ... Read more

February 24, 2017February 24, 2017

#ACTRIMS2017 – Sun Exposure May Lower Fatigue, Slow Disability Progression in MS

News

Spending more time in the sunshine could make people with multiple sclerosis (MS) feel more energetic, though dietary vitamin D intake’s effect is mixed, depending on what ... Read more

February 23, 2017February 23, 2017

#ACTRIMS2017 – Lemtrada Maintains Durable Positive Effects in MS Without Additional Treatment

News

Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the ... Read more

February 23, 2017February 23, 2017

#ACTRIMS2017 – Learning is Underway at Annual MS Confab

Columns, Engaging Thoughts

Editor’s note: Columnist Laura Kolaczkowski reports from ACTRIMS in Orlando, Fla. The second Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) got under way ... Read more

February 23, 2017February 23, 2017

#ACTRIMS2017 – Early MS Evidence Found in Asymptomatic First-degree Relatives of Patients

News

First-degree relatives of multiple sclerosis (MS) patients may develop asymptomatic disease, suggesting the need to further evaluate family members to develop timely prevention strategies. The study, “Investigating early ... Read more

February 23, 2017February 23, 2017

#ACTRIMS2017 – Airway Infections May Be More Common in MS Due to Altered Immune Response in Lungs

News

Disease processes in multiple sclerosis (MS) likely contribute to the increased sensitivity to airway infections seen in MS patients, a series of experiments in mice demonstrated. The ... Read more

February 21, 2017February 21, 2017

#ACTRIMS2017 – Phase 2 Trial Data Shows Better Walking Speeds in MS Patients Using ADS-5102

News

Results from a Phase 2 proof-of-concept study of ADS-5102 (amantadine HCl), showing that multiple sclerosis patients given the extended-release oral treatment improved their walking speed, will be presented at ACTRIMS 2017 this week. Findings ... Read more

February 20, 2017February 20, 2017

#ACTRIMS2017 – Forum for MS Research and Treatment Opens Feb. 23 in Orlando

News

The second annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), a forum for clinicians, researchers and other MS specialists to network and discuss the latest advances in ... Read more

Pin It on Pinterest